Bempedoic acid + Ezetimibe + Rosuvastatin + Atorvastatin
Pre-clinicalRecruiting 2 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Hypercholesterolemiia
Conditions
Primary Hypercholesterolemiia, Mixed Dyslipidemia
Trial Timeline
Feb 12, 2025 → Jan 31, 2028
NCT ID
NCT06686615About Bempedoic acid + Ezetimibe + Rosuvastatin + Atorvastatin
Bempedoic acid + Ezetimibe + Rosuvastatin + Atorvastatin is a pre-clinical stage product being developed by Daiichi Sankyo for Primary Hypercholesterolemiia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06686615. Target conditions include Primary Hypercholesterolemiia, Mixed Dyslipidemia.
What happened to similar drugs?
20 of 20 similar drugs in Primary Hypercholesterolemiia were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
3
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07474649 | Phase 3 | Recruiting |
| NCT06686615 | Pre-clinical | Recruiting |
Competing Products
20 competing products in Primary Hypercholesterolemiia